N4 Pharma PLC (N4P) — Cash Flow-to-Debt Ratio
N4 Pharma PLC (N4P) has a Cash Flow-to-Debt Ratio of -5.67x as of June 2025, meaning its operating cash flow of GBX-444.37K could theoretically repay -6% of its total liabilities (GBX78.37K) in one year. See how financially flexible is N4 Pharma PLC to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
N4 Pharma PLC Cash Flow-to-Debt Ratio (1991–2024)
Historical debt coverage capacity for N4 Pharma PLC across 34 annual periods. For the full cash flow conversion analysis, see cash flow conversion of N4 Pharma PLC.
Annual Cash Flow-to-Debt Ratio for N4 Pharma PLC (1991–2024)
Year-by-year debt coverage analysis for N4 Pharma PLC. Check N4 Pharma PLC cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -7.81x | GBX-971.50K | GBX124.37K | ▲ +47.2% |
| 2023 | -14.79x | GBX-1.21 Million | GBX81.73K | ▼ -39.1% |
| 2022 | -10.63x | GBX-828.26K | GBX77.89K | ▼ -27.6% |
| 2021 | -8.33x | GBX-1.77 Million | GBX212.73K | ▼ -2.1% |
| 2020 | -8.16x | GBX-1.38 Million | GBX169.08K | ▲ +21.4% |
| 2019 | -10.38x | GBX-806.00K | GBX77.68K | ▼ -46.7% |
| 2018 | -7.07x | GBX-1.34 Million | GBX190.12K | ▼ -33.3% |
| 2017 | -5.31x | GBX-950.80K | GBX179.22K | ▼ -8.6% |
| 2016 | -4.88x | GBX-376.00K | GBX77.00K | ▲ +90.4% |
| 2015 | -50.71x | GBX-862.00K | GBX17.00K | ▼ -11935.2% |
| 2014 | -0.42x | GBX-340.00K | GBX807.00K | ▼ -336.8% |
| 2013 | -0.10x | GBX-87.00K | GBX902.00K | ▲ +63.0% |
| 2012 | -0.26x | GBX-324.00K | GBX1.24 Million | ▼ -138.4% |
| 2011 | 0.68x | GBX996.00K | GBX1.47 Million | ▲ +182.7% |
| 2010 | 0.24x | GBX249.00K | GBX1.04 Million | ▼ -63.1% |
| 2009 | 0.65x | GBX755.00K | GBX1.16 Million | ▲ +296.0% |
| 2008 | -0.33x | GBX-184.00K | GBX554.00K | ▼ -210.0% |
| 2007 | 0.30x | GBX160.00K | GBX530.00K | ▲ +329.3% |
| 2006 | -0.13x | GBX-67.00K | GBX509.00K | ▼ -350.7% |
| 2005 | -0.03x | GBX-113.00K | GBX3.87 Million | ▼ -184.9% |
| 2004 | 0.03x | GBX140.00K | GBX4.07 Million | ▲ +90.9% |
| 2003 | 0.02x | GBX85.00K | GBX4.71 Million | ▲ +111.8% |
| 2002 | -0.15x | GBX-739.00K | GBX4.85 Million | ▼ -477.7% |
| 2001 | 0.04x | GBX210.00K | GBX5.21 Million | ▲ +185.2% |
| 2000 | -0.05x | GBX-380.00K | GBX8.03 Million | ▼ -141.6% |
| 1999 | -0.02x | GBX-171.00K | GBX8.73 Million | ▲ +92.7% |
| 1998 | -0.27x | GBX-2.72 Million | GBX10.10 Million | ▼ -165.5% |
| 1997 | -0.10x | GBX-2.66 Million | GBX26.17 Million | ▼ -218.5% |
| 1996 | 0.09x | GBX2.02 Million | GBX23.55 Million | ▲ +1225.3% |
| 1995 | 0.01x | GBX163.00K | GBX25.21 Million | ▼ -96.3% |
| 1994 | 0.18x | GBX3.34 Million | GBX18.88 Million | ▲ +591.9% |
| 1993 | 0.03x | GBX310.00K | GBX12.14 Million | ▼ -82.9% |
| 1992 | 0.15x | GBX2.72 Million | GBX18.22 Million | ▲ +223.7% |
| 1991 | -0.12x | GBX-2.42 Million | GBX20.05 Million | — |